5-Amino-1MQ
5-Amino-1-methylquinolinium
A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase) that increases NAD+ levels and metabolic rate. Non-peptide compound taken orally.
Typical Cost
$60-120/month
Status
Research
Peptide Profile
5-Amino-1MQ
Mechanism of Action
Inhibits NNMT enzyme, which is elevated in obesity and diabetes. Reduces methylation of nicotinamide, increasing NAD+ levels and activating sirtuins. Enhances metabolic rate and fat oxidation.
Common Dosages
oral
50-150mg
Daily · 8-12 weeks
Benefits
Increased metabolic rate
Enhanced fat oxidation
Improved body composition
Higher NAD+ levels
Better insulin sensitivity
Side Effects
Unknown long-term safety
Potential liver effects
Nausea
Headache
Key Research
NNMT inhibition in obesity models
Demonstrated reduced fat mass and improved glucose tolerance in animal models
Regulatory Status
Research chemical only. Not FDA-approved. No human clinical trials completed.
Contraindications
- ⚠Liver disease
- ⚠Pregnancy/breastfeeding
- ⚠Unknown interactions
Limited data makes this higher risk. SeraVia's proven formulations offer safer metabolic support for GLP-1 users.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.